This study is for people with Stage IV Non-Small Cell Lung Cancer (NSCLC). It looks at combining two medicines: **Interleukin-2 (IL-2)**, which may help boost the immune system, and **pembrolizumab**, a drug that helps the body's immune system fight cancer cells. The study will see how well these medicines work together and if they are safe.
Key Points to Consider:
- **Treatment Schedule**: Pembrolizumab is given by IV every 3 weeks, and IL-2 is given twice daily for 3 weeks. After 3 weeks, only pembrolizumab continues.
- **Study Duration**: You will be followed for 6 weeks after treatment ends.
- **Eligibility**: Participants should not have had prior treatments for advanced NSCLC and must agree to use birth control during the study.
Participants must be at least 18 years old, have Stage IV NSCLC, and meet other health criteria. If you are interested, ensure you meet these conditions and are ready for the treatment schedule. This study may offer insights into better managing lung cancer, but make sure to understand potential risks and benefits before participating.
How understandable was the trial content above?
Hard to understand
Easy to understand